Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Replimune Group, Inc. securities for the period between November 22, 2024, and July 21, 2025, due to alleged misleading statements regarding the IGNYTE trial [1][5]. Group 1: Lawsuit Details - The lawsuit claims that defendants made materially false and misleading statements about the IGNYTE trial's prospects, which led to the FDA deeming the trial inadequate [5]. - Investors who purchased Replimune securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by September 22, 2025, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Hims & Hers Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the lawsuit is from April 29, 2025, to June 23, 2025, inclusive [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by August 25, 2025 [2] Group 2: Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions [3] - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - The firm has consistently ranked in the top 4 for securities class action settlements since 2013, recovering hundreds of millions for investors [3] Group 3: Case Allegations - The lawsuit alleges that Hims made false and misleading statements regarding its partnership with Novo Nordisk A/S, particularly about the availability of the weight-loss drug Wegovy [4] - Specific claims include that Hims misrepresented the nature of its collaboration with Novo and the offerings of compounded semaglutide products [4] - The lawsuit asserts that when the true details were revealed, investors suffered damages [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Biohaven Ltd. securities during the specified class period of the upcoming lead plaintiff deadline on September 12, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Biohaven securities between March 24, 2023, and May 14, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the September 12, 2025 deadline [2]. - The lawsuit claims that throughout the class period, Biohaven made false and misleading statements regarding the regulatory prospects of its drug troriluzole and its efficacy for treating bipolar disorder, which negatively impacted the company's business and financial condition [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has been ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [3]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [3].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Alto Neuroscience, Inc. common stock, alleging that the company made materially false and misleading statements regarding its business and prospects during the Class Period from February 2, 2024, to October 22, 2024 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Alto's offering documents contained false statements about the effectiveness of ALTO-100 in treating major depressive disorder, overstating its clinical, regulatory, and commercial prospects [5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by September 19, 2025, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone [4].

Core Viewpoint - A class action lawsuit has been filed against Fiserv, Inc. for misleading statements regarding its Clover platform and the forced migration of Payeezy merchants, which allegedly concealed a slowdown in new merchant business and led to significant merchant losses [1][5]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of Fiserv common stock between July 24, 2024, and July 22, 2025 [1]. - The lawsuit claims that Fiserv made false statements about Clover's growth strategies and business prospects, which were materially misleading [5]. - Allegations include that Fiserv forced Payeezy merchants to migrate to Clover, resulting in temporary revenue boosts that concealed underlying issues [5]. Group 2: Investor Information - Investors who purchased Fiserv stock during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by September 22, 2025, to represent the class in the lawsuit [1][3]. Group 3: Rosen Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [4]. - The firm has been recognized for its leadership in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of GeneDx Holdings Corp due to allegations of materially misleading business information [1] Group 1: Legal Actions and Investigations - Shareholders who purchased GeneDx securities may be entitled to compensation through a class action without any out-of-pocket fees [2] - A report by Grizzly Research accused GeneDx of committing widespread fraud, claiming that its growth is an illusion driven by fraudulent schemes [3] Group 2: Stock Performance - Following the allegations from Grizzly Research, GeneDx's stock price fell by $4.84, or 6.7%, closing at $67.18 per share on February 5, 2025 [3] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Luminar Technologies, Inc. securities during the specified Class Period, highlighting potential misconduct by the company's leadership that may have adversely affected investors [1][5]. Group 1: Lawsuit Details - The class action lawsuit is filed for securities purchased between March 20, 2025, and May 14, 2025, inclusive [1]. - Investors who purchased Luminar securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must move the Court by September 22, 2025, to represent other class members in the litigation [3]. Group 2: Allegations Against Luminar - The lawsuit alleges that Luminar's President, CEO, and Chairman, Austin Russell, engaged in undisclosed conduct that led to an inquiry by the Audit Committee [5]. - This conduct posed a material risk of Russell being removed from his positions, which could adversely affect Luminar's business operations and competitive standing [5]. - The lawsuit claims that Luminar lacked a reasonable basis for its financial guidance due to these undisclosed risks, leading to materially false and misleading public statements [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing investor rights [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Petco Health and Wellness Company, Inc. securities between January 14, 2021, and June 5, 2025, of the upcoming lead plaintiff deadline on August 29, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Petco securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by August 29, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that throughout the Class Period, defendants made false and misleading statements regarding Petco's business model and pandemic-related growth, which were unsustainable [5]. - It is claimed that the strength of Petco's differentiated product strategy was overstated, and the true scope of issues affecting the company was downplayed [5]. - The lawsuit asserts that defendants overstated Petco's ability to deliver sustainable, profitable growth, leading to investor damages when the true details became public [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased PepGen Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on August 8, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought PepGen securities between March 7, 2024, and March 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by August 8, 2025 [2]. - The lawsuit claims that throughout the Class Period, PepGen made false and misleading statements regarding the effectiveness and safety of PGN-EDO51, as well as the CONNECT2 study's suitability for FDA approval [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [3]. - In 2019, Rosen Law Firm secured over $438 million for investors, showcasing its capability in handling significant cases [3].

NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of iRobot Corporation (NASDAQ: IRBT) between January 29, 2024 and March 11, 2025, both dates inclusive (the “Class Period”), of the important September 5, 2025 lead plaintiff deadline. SO WHAT: If you purchased iRobot securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. ...